Skip to main content

This website is intended exclusively for healthcare professionals residing and/or working in Bahrain.

Home | go to homepage
SCIENCE
  • SCIENCE
  • Asthma
  • Atopic Dermatitis
  • Cardiovascular
    • Cardiovascular
    • Atherothrombosis
    • Dyslipidemia
    • Thrombosis
  • Diabetes
  • Eosinophilic Esophagitis
  • Multiple Sclerosis
  • Nasal Polyps
  • Prurigo Nodularis
  • Rare Diseases
  • Vaccines
    • Vaccines
    • Influenza
    • Meningitis
    • Pertussis & Polio
    • RSV
PATIENT SUPPORT
  • PATIENT SUPPORT
  • Atopic Dermatitis
  • Diabetes
    • Diabetes
    • Tools And Resources
      • Tools And Resources
      • Toujeo Welcome Pack
      • Soliqua Welcome Pack
      • Pre-Ramadan assessment and Risk calculation for diabetic patients during Ramadan
      • Clinical and economic value of SOLIQUA - Pharmacist perspective
  • Nasal Polyps
  • Rare Diseases
PRODUCTS
  • PRODUCTS
  • Amaryl®
  • Apidra®
  • Aprovel®
  • Aubagio®
  • Cerezyme
  • Clexane®
  • Depakine®
  • Dupixent®
    • Dupixent®
    • Atopic Dermatitis
    • Asthma
    • Nasal Polyps
  • Lantus®
  • Lemtrada®
  • Plavix®
  • Praluent®
  • Soliqua®
    • Soliqua®
    • Soliqua®
    • SoliMix Study
    • For a Peaceful Ramadan
    • Soli-Simplify Study
  • Tavanic®
  • Toujeo®
    • Toujeo®
    • Toujeo®
    • For a Peaceful Ramadan
    • Time-in-Range
    • Real world Evidences
  • LOGIN
  • SIGN UP
  • SEARCH
    Home | go to homepage
  • LOGIN
  • SIGN UP
  • SEARCH
    Home | go to homepage
    SCIENCE
    • SCIENCE
    • Asthma
    • Atopic Dermatitis
    • Cardiovascular
      • Cardiovascular
      • Atherothrombosis
      • Dyslipidemia
      • Thrombosis
    • Diabetes
    • Eosinophilic Esophagitis
    • Multiple Sclerosis
    • Nasal Polyps
    • Prurigo Nodularis
    • Rare Diseases
    • Vaccines
      • Vaccines
      • Influenza
      • Meningitis
      • Pertussis & Polio
      • RSV
    PATIENT SUPPORT
    • PATIENT SUPPORT
    • Atopic Dermatitis
    • Diabetes
      • Diabetes
      • Tools And Resources
        • Tools And Resources
        • Toujeo Welcome Pack
        • Soliqua Welcome Pack
        • Pre-Ramadan assessment and Risk calculation for diabetic patients during Ramadan
        • Clinical and economic value of SOLIQUA - Pharmacist perspective
    • Nasal Polyps
    • Rare Diseases
    PRODUCTS
    • PRODUCTS
    • Amaryl®
    • Apidra®
    • Aprovel®
    • Aubagio®
    • Cerezyme
    • Clexane®
    • Depakine®
    • Dupixent®
      • Dupixent®
      • Atopic Dermatitis
      • Asthma
      • Nasal Polyps
    • Lantus®
    • Lemtrada®
    • Plavix®
    • Praluent®
    • Soliqua®
      • Soliqua®
      • Soliqua®
      • SoliMix Study
      • For a Peaceful Ramadan
      • Soli-Simplify Study
    • Tavanic®
    • Toujeo®
      • Toujeo®
      • Toujeo®
      • For a Peaceful Ramadan
      • Time-in-Range
      • Real world Evidences
  • LOGIN
  • SIGN UP
  • SEARCH
    • Home
    • Science
    • Cardiovascular

    Cardiovascular Diseases

    Learn about the latest trends, discover events and innovations in the changing world of cardiovascular disease.

    Science in Cardiovascular Diseases

    Get a 360º view and stay up-to-date on cardiovascular disease with content selected for you

    ODYSSEY Outcomes

    NEJM Odyssey Outcomes

    Odyssey Outcomes - Mortality

    Odyssey Outcomes - CABG Results

    Odyssey Outcomes - PVD Results

    PCSK9 inhibitors and ACS

    VTE Comparison of Pregnancy-Specific Risk Scoring Systems in Hospitalized Maternity Patients

    Utility of Pregnancy-Adapted YEARS Algorithm in Diagnosis of Pulmonary Embolism

    Changing trends in VTE: Pulmonary Embolism Cases on Rise within the Last Decade

    Clopidogrel Based Strategies in ACS

    Clopidogrel vs Ticagrelor in ACS

    P2Y12 Inhibitors After Coronary Stenting

    SEE EVERYTHING

    Inspiration and innovation

    Get inspired and stay at the forefront of innovation with the following resources

    PCSK9 inhibitors and ACS

    VTE Comparison of Pregnancy-Specific Risk Scoring Systems in Hospitalized Maternity Patients

    Utility of Pregnancy-Adapted YEARS Algorithm in Diagnosis of Pulmonary Embolism

    Key Learnings in Dyslipidemia by Prof. Kausik Ray - 2021 EAS Congress

    Clinical practice experience in patients with familial hypercholesterolemia (FH) from the SAFEHEART registry

    VTE prevention for acutely ill patients

    VTE Risk Assessment in Surgical Patients

    Improving Lipid Management for Patients Post-ACS

    VTE prophylaxis in medically ill patients

    Evaluation of comparative efficacy and safety of thromboprophylaxis agents among critically ill patients

    Understanding de-escalation in antiplatelet therapy

    Prognostic impact of achieving LDL cholesterol guidelines

    SEE EVERYTHING

    Events

    Stay up to date and register for the latest events and view webinar recordings.

    Venous Thromboembolism Burden

    Sanofi Thrombosis Summit

    24:30

    Dyslipidemia Webinars: Optimizing Dyslipidemia management​

    Challenges of VTE Prophylaxis in Surgery

    Venous Thromboembolism in Acutely Medically Ill Patients

    Hypertension - The Most Important Disease in Medicine

    Hypertension - The Most Important Disease in Medicine II

    Dyslipidemia Expert Exchange: Best practice approaches in dyslipidemia management

    19:24

    VTE Safety Zone: Assessing the VTE Risk in Hospital and Beyond

    06:13

    VTE Safety Zone: The Role of Thromboprophylaxis for the Prevention of VTE

    VTE Safety Zone: VTE in general surgery from risk assessment to appropriate thromboprophylaxis

    06:58

    VTE Safety Zone: Primary VTE Prophylaxis in Patients with Cancer Undergoing Major Abdominal/Pelvic Surgery

    SEE EVERYTHING
    Home | go to homepage

    SANOFI, Level 3, One JLT, Jumeirah Lake Towers (JLT), DMCC, PO Box 53899, Dubai, UAE |

    Tel.: +971 4 550 3600 | Fax: +971 4 5521050

    For further Medical Information:

    please contact: +971 565776791 or Email: medical-information.gulf@sanofi.com

    To report an adverse event:

    please call: +971 561747001 or Email: Gulf.pharmacovigilance@sanofi.com

    To report any product technical complaints, kindly contact: Email: quality.greatergulf@sanofi.com

     

    MAT-BH-2100734/V4/Oct 2022

    • Legal notice
    • Cookie policy
    • Privacy policy
    • Sitemap
    • Change country

    YOU WILL NOW BE LEAVING THE SITE

    By clicking on this link, you will be leaving Campus Sanofi website and going to another, entirely independent website.
    Please note: Sanofi provides these links as a service to its website visitors and users; however, Sanofi takes no responsibility for the information on any website but their own.

    Continue
    This website is intended exclusively for healthcare professionals residing and/or working in Bahrain.
     
    Please choose if you are a healthcare professional and wish to continue on this site or if you are a member of the public to be redirected to the Sanofi website.